Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 8Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Stomach Neoplasms 2Sezary Syndrome 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Gallbladder Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1

Interventions

Taxes 2Paclitaxel 2Immunoglobulin G 2Disulfides 2Carboplatin 2Bevacizumab 2trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1ixabepilone 1cediranib 1Trastuzumab 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1MK 2206 1GSK2141795 1Epothilones 1Cisplatin 1AZD 6244 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Endometrial Adenocarcinoma × MK 2206 × Clear all
NCT01307631 2022-02-11

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 9 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡